Antineoplastic patches for external use of bullatacin

An anti-tumor and patch technology, applied in the field of anti-tumor external patches, can solve the problems of skin irritation and toxicity, reduce economic costs, etc., and achieve the effects of less damage to normal cells, lower economic costs, and reduced dosage of administration

Inactive Publication Date: 2008-10-29
贵州正鑫实业有限公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The technical problem to be solved by the present invention is to provide a kind of anti-tumor external patch of blatasine, which has not only solved the disadvantages of large toxic and side effects of oral or intravenous administration of anti-tumor drugs in the past, but also overcomes the harmful effects of traditional external patches on the skin. It has the disadvantages of high irritation and certain toxicity, and reduces the economic cost

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: The blatacine anti-tumor external patch of the present invention includes a backing layer, a drug reservoir and an anti-adhesive layer. A cotton medical non-woven fabric with good air permeability is used as the backing layer and the drug reservoir The polymer gel acrylate pressure-sensitive adhesive is used as the adhesive, containing the formulated blatacine liquid, and the silicone oil anti-sticking treatment polyester film is used as the anti-sticking layer.

[0028] Blatacine medicinal solution is to dissolve 198 grams of blatacine parts in a 1100ml mixture of anhydrous ethanol and propylene glycol with a volume ratio of 1:1, stir well and mix well to make 20400 patches for external use. (Size: 7×10cm).

Embodiment 2

[0029] Example 2: Preparation method of blatacine anti-tumor topical patch, which includes the following steps: (1) Ingredients: dissolve 198 grams of blatacine part medicine in absolute ethanol with a volume ratio of 1:1 In the 1100ml mixture of propylene glycol and propylene glycol, fully stir to make it evenly mixed; (2) Glue preparation: pressure-sensitive adhesive produced by the production process of acrylate pressure-sensitive adhesive; (3) Coating: Blatacine Mix the mixture of high-quality, absolute ethanol and propylene glycol with the pressure-sensitive adhesive after heating and melting, and coat it on the anti-sticking layer, and then cover the backing layer; (4) Slice: Cut into appropriate size (5×7cm) , 7×10cm, 9×12cm and other specifications); dry and cool, sealed and packaged with aluminum-plastic composite film.

Embodiment 3

[0030] Example 3: The following will further illustrate the beneficial effects of the drug of the present invention through drug clinical trials:

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a Bulataxin anti-tumor external patch, which consists of a back lining, a drug storage and an anti-adhesive layer. Breathable cotton medical non-woven cloth is selected as the back lining, the drug storage takes a macromolecule gel acrylate pressure-sensitive adhesive as an adhesive, containing the mixed Bulataxin solution, a polyester film through silicone oil anti-adhesive treatment is taken as the anti-adhesive layer. The invention not only solves the shortcomings of significant toxicity and side effects of oral intake or intravenous administration of past anti-tumor drugs, but also overcomes the shortcomings of significant skin irritation and toxicity of traditional external patches and reduces the economic cost.

Description

Technical field [0001] The invention relates to an anti-tumor external administration preparation, in particular to an anti-tumor external patch. Background technique [0002] Annonaceae (Annonaceae) is a large plant population in tropical and subtropical regions. The family contains alkaloids, terpenes, flavonoids, annonaceae, polyoxycyclohexene and styrene lactones. Among them, the last three types of compounds have anti-tumor activity and have aroused widespread interest among scholars from various countries. Annonaceous acetogenins are a new type of natural product first discovered in Annonaceae in 1982. Annonaceous lactone has a wide range of physiological activities, the most typical of which are anti-tumor activity and cytotoxicity. Studies have shown that most of the annona lactone compounds generally have a strong cytotoxic effect on tumor cells cultured in vitro. [0003] At present, the incidence of tumors and cancers worldwide is increasing year by year. Radiation, ch...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/365A61P35/00
Inventor 杨正强杨仁洲脱冰林周显勇张安袁胜伟
Owner 贵州正鑫实业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap